Press Releases

Date Title and Summary Additional Formats
Toggle Summary ArQule Announces Publication of Preclinical Data for ARQ 531, a Reversible Inhibitor of Both Wild Type and Mutant BTK
Data Support ARQ 531 as a Potential First- and Best-In-Class Reversible BTK Inhibitor, with the Potential to Address Emerging Resistance to Irreversible BTK Inhibitors BURLINGTON, Mass. --(BUSINESS WIRE)--Aug. 13, 2018-- ArQule, Inc. (Nasdaq:ARQL), today announced the publication of preclinical
View HTML
Toggle Summary ArQule Reports Second Quarter 2018 Financial Results
Conference call scheduled today at 9:00 a.m. ET BURLINGTON, Mass. --(BUSINESS WIRE)--Aug. 1, 2018-- ArQule , Inc. (Nasdaq: ARQL) today announced its financial results for the second quarter of 2018. For the quarter ended June 30, 2018 , the Company reported net income of $5,156,000 or $0.05 per
View HTML
Toggle Summary ArQule to Report Second Quarter 2018 Financial Results on August 1, 2018
BURLINGTON, Mass. --(BUSINESS WIRE)--Jul. 18, 2018-- ArQule , Inc. (Nasdaq: ARQL) today announced it will report financial results for the second quarter of 2018 before the market opens on Wednesday, August 1, 2018 . The Company will hold a conference call and webcast on the same day at 9:00 a.m.
View HTML
Toggle Summary ArQule Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
BURLINGTON, Mass. --(BUSINESS WIRE)--Jul. 13, 2018-- ArQule, Inc. (Nasdaq: ARQL) today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,650,000 shares at the
View HTML
Toggle Summary ArQule Announces Pricing of $60.5 Million Public Offering of Common Stock
BURLINGTON, Mass. --(BUSINESS WIRE)--Jul. 11, 2018-- ArQule, Inc. (Nasdaq: ARQL) today announced the pricing of an underwritten public offering of 11 million shares of its common stock at a price to the public of $5.50 per share. ArQule has granted the underwriters a 30-day option to purchase up to
View HTML
Toggle Summary ArQule Announces Commencement of Proposed Public Offering of Common Stock
BURLINGTON, Mass. --(BUSINESS WIRE)--Jul. 10, 2018-- ArQule, Inc. (Nasdaq: ARQL) today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock. In connection with the offering, ArQule expects to grant the
View HTML
Toggle Summary ArQule Added to the Russell 2000® Index
BURLINGTON, Mass. --(BUSINESS WIRE)--Jun. 25, 2018-- ArQule, Inc. (Nasdaq: ARQL) today announced that it has been added to the Russell 2000 ® Index, a subset of the Russell 3000 ®  Index, effective as of market closing on June 22, 2018 , at the conclusion of the annual Russell US Index
View HTML
Toggle Summary ArQule Presents Results from Ongoing Phase 1 Dose Escalation Study of its Reversible BTK Inhibitor, ARQ 531
BURLINGTON, Mass. --(BUSINESS WIRE)--Jun. 15, 2018-- ArQule, Inc. (Nasdaq:ARQL) today is presenting preliminary results from the Company’s Phase 1 dose escalation study for ARQ 531, an orally bioavailable, potent and reversible inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase
View HTML
Toggle Summary ArQule to Present at The JMP Securities Life Sciences Conference on June 21, 2018
BURLINGTON, Mass. --(BUSINESS WIRE)--Jun. 14, 2018-- ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci , Chief Executive Officer, and Dr. Brian Schwartz , Chief Medical Officer and Head of Research and Development, will present at The JMP Securities Life Sciences Conference on June 21,
View HTML
Toggle Summary ArQule to Present Clinical Data for its BTK Inhibitor, ARQ 531, at the 23rd Congress of the European Hematology Association (EHA)
Data strengthens clinical profile and supports further dose escalation for ARQ 531 BURLINGTON, Mass. --(BUSINESS WIRE)--Jun. 7, 2018-- ArQule, Inc. (Nasdaq: ARQL) today announced clinical data from the company-sponsored ARQ 531-101 Phase 1 dose escalation study in subjects with relapsed or
View HTML

Questions or Concerns?

Please feel free to contact by one of the methods below

Online Form   Call (781) 994-0300

These archived presentations and related materials are provided for reference by ArQule, Inc. Information contained in the materials was current only as of the date of the event. ArQule, Inc. does not update or delete outdated information contained in these materials, and it expressly disclaims any obligation to do so. The materials are property of ArQule, Inc. and any use, dissemination or republication of the files is prohibited without the express written consent of ArQule, Inc.